Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Drug Clearance: Overview

Drug Clearance: Overview

Drug elimination refers to drug removal from the body, either through urine or bile, by the kidneys or liver, respectively. A pharmacokinetic parameter, drug clearance, measures the efficiency of drug removal from the bloodstream within a specific time frame. It is calculated as the rate at which a drug is eliminated from plasma divided by the drug's concentration in plasma.
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including the...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Coagulation is associated with renal function decline and chronic kidney disease in people living with HIV in South Africa.

Frontiers in nephrology·2026

Same author

Triple-Negative Breast Cancer: Molecular Subtypes; Immune Escape; Limitations of Current Immunotherapy; and the BTLA/HVEM/CD160 Axis as an Emerging Target.

Current issues in molecular biology·2026

Same author

Systemic Protein Biomarkers, Composite Blood Inflammatory Indices and Cellular Ratios in Metastatic Colorectal Cancer: Potential Therapeutic Targets.

Diseases (Basel, Switzerland)·2026

Same author

The Potassium-Uptake Systems, Trk and Kdp, Coordinately Contribute to Growth Regulation and Survival of <i>M. tuberculosis</i> in Ion-Depleted and Acidic Environments.

International journal of molecular sciences·2026

Same author

The Effects of In Utero HIV and Antiretroviral Therapy Exposure on Infant T-Cell and Monocyte Activation, Function, and Regulation of Immune-Modulatory Pathways.

Mediators of inflammation·2026

Same author

Humoral and cellular immunogenicity of COVID-19 vaccine boosters in participants with advanced HIV disease.

The Journal of infection·2026

Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026

Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026

Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026

Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026

Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026

Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 28, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Clofazimine: current status and future prospects.

Moloko C Cholo¹, Helen C Steel, P B Fourie

¹Medical Research Council Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria and Tshwane Academic Division of the National Health Laboratory Service, Pretoria, South Africa. moloko.cholo@mrc.ac.za

The Journal of Antimicrobial Chemotherapy

|October 25, 2011

Summary

This summary is machine-generated.

Clofazimine shows promise for treating multidrug-resistant tuberculosis and autoimmune diseases due to its antimycobacterial and anti-inflammatory properties. Recent advancements may enhance its therapeutic efficacy and versatility.

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Related Experiment Videos

Last Updated: May 28, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

Area of Science:

Pharmacology
Infectious Diseases
Immunology

Background:

Clofazimine, a lipophilic riminophenazine antibiotic, exhibits antimycobacterial and anti-inflammatory activities.
Its efficacy is established in leprosy but not yet in human tuberculosis, despite in vitro activity against multidrug-resistant Mycobacterium tuberculosis strains.

Purpose of the Study:

To critically evaluate recent developments in clofazimine research.
To assess the potential impact of novel targets, mechanisms, and drug delivery technologies on clofazimine's therapeutic efficacy and versatility.

Main Methods:

Literature review of recent scientific insights and technological advancements related to clofazimine.
Critical evaluation of existing data on clofazimine's antimicrobial and anti-inflammatory activities.
Assessment of innovative drug delivery technologies for clofazimine.

Main Results:

Recent insights into novel targets and mechanisms of action have renewed interest in clofazimine.
Innovative drug delivery technologies offer potential for improved clofazimine formulations.
Clofazimine shows potential as a therapy for multidrug- and extensively multidrug-resistant tuberculosis and autoimmune diseases.

Conclusions:

Clofazimine's therapeutic potential extends beyond leprosy, particularly for resistant tuberculosis and autoimmune conditions.
Advancements in understanding its mechanisms and delivery systems are crucial for realizing its full therapeutic versatility.
Further research and clinical evaluation are warranted to optimize clofazimine-based therapies.